These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes. Little PJ; Cohen N; Morahan G ScientificWorldJournal; 2009 Mar; 9():224-8. PubMed ID: 19347233 [No Abstract] [Full Text] [Related]
3. Is there a role for imatinib in inflammatory bowel disease? De Backer O; Lefebvre RA Inflamm Bowel Dis; 2008 Apr; 14(4):579-81. PubMed ID: 18050299 [No Abstract] [Full Text] [Related]
5. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771 [TBL] [Abstract][Full Text] [Related]
6. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147 [TBL] [Abstract][Full Text] [Related]
7. Second-generation BCR-ABL kinase inhibitors in CML. Tanimoto T; Hori A; Tsubokura M N Engl J Med; 2010 Oct; 363(17):1672; author reply 1673-5. PubMed ID: 20961253 [No Abstract] [Full Text] [Related]
8. Imatinib for the treatment of rheumatic diseases. Paniagua RT; Robinson WH Nat Clin Pract Rheumatol; 2007 Apr; 3(4):190-1. PubMed ID: 17396105 [No Abstract] [Full Text] [Related]
9. Interview with Jürg Zimmermann, global head of oncology & exploratory chemistry at Novartis. Zimmermann J Future Med Chem; 2009 Nov; 1(8):1395-8. PubMed ID: 21426055 [TBL] [Abstract][Full Text] [Related]
10. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812 [TBL] [Abstract][Full Text] [Related]
12. Src kinase signaling in leukaemia. Li S Int J Biochem Cell Biol; 2007; 39(7-8):1483-8. PubMed ID: 17350876 [TBL] [Abstract][Full Text] [Related]
13. Imatinib: as adjuvant therapy for gastrointestinal stromal tumor†: profile report. Sanford M; Scott LJ BioDrugs; 2011 Jun; 25(3):191-2. PubMed ID: 21627342 [No Abstract] [Full Text] [Related]
14. Imatinib treatment of generalized localized scleroderma (morphea). Moinzadeh P; Krieg T; Hunzelmann N J Am Acad Dermatol; 2010 Nov; 63(5):e102-4. PubMed ID: 20950732 [No Abstract] [Full Text] [Related]
15. Imatinib does not impair gonadal function. Chuah C Leuk Res; 2012 Mar; 36(3):262-3. PubMed ID: 22129479 [No Abstract] [Full Text] [Related]
16. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia. Taylor MJ; Scuffham PA Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798 [TBL] [Abstract][Full Text] [Related]
17. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Soverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; Rosti G; Baccarani M Lancet Oncol; 2007 Mar; 8(3):273-4. PubMed ID: 17329198 [No Abstract] [Full Text] [Related]